查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1968498

淚囊炎市場－全球產業規模、佔有率、趨勢、機會、預測：按適應症、通路、地區和競爭格局分類，2021-2031年

Dacryocystitis Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球淚囊炎市場預計將從 2025 年的 2.0869 億美元成長到 2031 年的 2.6621 億美元，複合年成長率為 4.14%。

該市場涵蓋由鼻淚管阻塞引起的淚囊發炎的診斷和治療性介入，這種疾病會導致疼痛性腫脹和流淚過多。推動市場成長的主要因素包括全球人口老化，老齡化罹患淚道狹窄的風險較高，以及臉部創傷和需要醫療干預的慢性眼部感染疾病不斷增加。

市場概覽
預測期 2027-2031
市場規模：2025年 2.0869億美元
市場規模：2031年 2.6621億美元
複合年成長率：2026-2031年 4.14%
成長最快的細分市場 急性期
最大的市場 北美洲

此外，兒童先天性鼻淚管阻塞的穩定發生率確保了藥物治療和手術矯正的穩定需求，從而建立了不受技術趨勢波動影響的穩定市場基礎。然而，術後失敗的風險以及再血管再阻塞難以處理等因素阻礙了市場擴張。復發率可能會使患者望而卻步，並可能影響保險報銷。根據美國眼整形與重組外科學會2024年的數據，鼻淚管吻合術的手術成功率在85.3%至91.4%之間，這意味著仍有持續失敗的可能，進而影響長期臨床療效。

市場促進因素

老年人口的快速成長是全球淚囊炎市場的主要促進因素，老年人極易感染眼部感染疾病。隨著人口結構老化加劇，與老齡化的鼻淚管阻塞的發生率顯著上升，從而對藥物和手術治療方法產生了持續的需求。由於與老齡化相關的生理變化會損害淚液排放系統，因此老年人群對市場收入尤其重要。根據美國國立衛生研究院 (NIH) 2024 年 4 月發布的一份報告，65 歲及以上人群的視力相關疾病盛行率仍然很高，約為每 10 萬人中有 40,966 例，這表明眼科患者數量持續成長。

同時，內視鏡技術和雷射治療的日益普及正在改變市場格局。這些技術為傳統體外手術提供了微創替代方案，透過減少臉部疤痕和縮短恢復時間，提高了患者的接受度。根據2024年3月《美國耳鼻喉科雜誌》的報道，初次內視鏡下鼻淚管吻合術的一年功能成功率達92.62%。此外，該技術的適用人群正在向更年輕的群體擴展。根據2024年6月《美國兒童與兒童眼科協會雜誌》的報道，兒童急性淚囊炎的發生率為每10萬人243例，凸顯了各年齡層對專業照護的需求。

市場挑戰

術後失敗率高以及血管再阻塞處理相關的生理難題是全球淚囊炎治療市場成長的主要障礙。這種臨床上的不確定性削弱了患者對手術治療的信心，尤其是在老年患者中，他們難以從侵入性手術中恢復，從而阻礙了市場擴張。當治療的主要療效因復發風險而降低時，選擇性淚道手術的普及速度就會放緩，而再次手術的需求也會給醫保報銷模式帶來複雜的問題，因為支付方需要評估高再治療率干預措施的長期價值。

近期行業數據進一步凸顯了臨床療效方面持續存在的差距，並強調了現有標準療法的局限性。美國眼科學會 (ARVO) 引用的一項 2024 年臨床隊列研究發現，約 19.6% 的淚囊炎患者在接受手術治療後仍有流淚過多的問題。這項統計數據顯示症狀緩解率極低，並對相關手術器械和療法的商業性可行性產生了負面影響。只要近五分之一的患者仍面臨持續性症狀，市場在將這些解決方案推廣至更廣泛人群方面就將面臨挑戰。

市場趨勢

市場結構性轉變的一個顯著趨勢是淚道手術擴大轉移到門診手術中心（ASC）。這主要是由於降低成本和提高營運效率的需求。與傳統醫院不同，門診手術中心為淚囊鼻腔吻合術等特定手術提供了高效的環境，有助於降低設施成本並縮短患者等待時間。更優的工作流程指標也支持了這項轉變。例如，一篇發表於2024年12月的ASC新聞報導指出，門診手術中心的平均手術室週轉時間約為11.9分鐘，這一速度促使支付方和外科醫生將常規手術轉移到門診進行。

同時，採用抗生素管理通訊協定正成為應對淚道感染疾病中抗藥性病原體日益普遍的關鍵趨勢。隨著對標準預防性治療的抗藥性不斷增強，臨床醫生正逐漸拋棄經驗性用藥，轉而採用基於細菌培養的藥物治療，以避免急性淚囊炎治療失敗。鑑於該疾病的細菌學特徵日益複雜，這種轉變至關重要。根據美國國立衛生研究院2024年2月發布的《成人淚囊炎研究》，抗藥性金黃色葡萄球菌（MRSA）和銅綠假單胞菌分別佔急性病例分離病原體的28.1%，加速了全球靶向抗菌策略的推廣應用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球淚囊炎市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（急性、慢性、先天性、淚囊炎、其他）
    • 分銷通路（醫院藥局、藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美淚囊炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲淚囊炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區淚囊炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲淚囊炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲淚囊炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球淚囊炎市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Viatris Inc.
  • GlaxoSmithKline PLC
  • FCI Ophthalmics Inc.
  • Merck & Co., Inc.
  • Kaneka Corporation
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Orex Pharma Pvt Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23830

The Global Dacryocystitis Market is projected to expand from USD 208.69 Million in 2025 to USD 266.21 Million by 2031, achieving a compound annual growth rate of 4.14%. This market encompasses diagnostic and therapeutic interventions for lacrimal sac inflammation, a condition frequently resulting from nasolacrimal duct obstruction that causes painful swelling and epiphora. Growth is primarily propelled by an aging global population susceptible to involutional stenosis, alongside increasing incidences of facial trauma and chronic ocular infections requiring medical attention.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 208.69 Million
Market Size 2031USD 266.21 Million
CAGR 2026-20314.14%
Fastest Growing SegmentAcute
Largest MarketNorth America

Additionally, the steady prevalence of congenital nasolacrimal duct obstruction in pediatric patients ensures a reliable demand for both pharmaceutical treatments and surgical corrections, creating a stable market foundation irrespective of temporary technological trends. However, market expansion faces hurdles due to the risks associated with post-surgical failure and the difficulties of managing restenosis, as recurrence rates can discourage patients and complicate reimbursement. Data from the American Society of Ophthalmic Plastic and Reconstructive Surgery in 2024 indicated that surgical success rates for dacryocystorhinostomy ranged from 85.3% to 91.4%, underscoring a persistent margin of failure that affects long-term clinical results.

Market Driver

The rapidly growing geriatric population, which is highly susceptible to ocular infections, acts as a major driver for the Global Dacryocystitis Market. As demographics shift toward an older median age, the incidence of involutional nasolacrimal duct obstruction rises substantially, generating consistent demand for pharmacological and surgical solutions. This demographic is particularly vital for market revenue due to age-related physiological changes that impair the lacrimal drainage system. According to the National Institutes of Health in April 2024, the prevalence of vision-related conditions remains severe among those aged 65 and older, affecting approximately 40,966 per 100,000 individuals and ensuring a steady stream of patients for ophthalmologic care.

Simultaneously, the market is being transformed by the increasing utilization of endoscopic techniques and laser therapies, which offer minimally invasive alternatives to conventional external surgeries. These advancements improve patient uptake by reducing facial scarring and recovery times, with the American Journal of Otolaryngology reporting in March 2024 that primary endoscopic dacryocystorhinostomy achieved a 92.62% functional success rate after one year. Furthermore, the market's scope extends to younger populations; the Journal of AAPOS noted in June 2024 that the incidence of acute dacryocystitis in pediatric groups stands at 243 per 100,000, emphasizing the need for specialized care across all age demographics.

Market Challenge

The significant potential for post-surgical failure and the physiological difficulties involved in managing restenosis present a major obstacle to the growth of the Global Dacryocystitis Market. This clinical uncertainty suppresses market expansion by eroding patient confidence in surgical options, particularly among the elderly for whom recovery from invasive procedures is more challenging. When the primary benefit of treatment is undermined by the risk of recurrence, the adoption of elective lacrimal surgeries slows, while the need for revision procedures creates complications for reimbursement models as payers evaluate the long-term value of interventions with high re-treatment rates.

Recent industry data further illuminates this persistent gap in clinical efficacy, highlighting the limitations of existing standard-of-care treatments. A 2024 clinical cohort study cited by the Association for Research in Vision and Ophthalmology found that approximately 19.6% of patients continued to suffer from epiphora even after surgical intervention for dacryocystitis. This statistic indicates a notable failure rate regarding symptom resolution, which negatively affects the commercial viability of surgical devices and therapeutics; as long as nearly one in five patients experiences persistent symptoms, the market encounters difficulties in expanding these solutions to a wider audience.

Market Trends

A significant structural shift in the market is the migration of lacrimal procedures to Ambulatory Surgical Centers (ASCs), driven by the demand for cost containment and operational efficiency. Unlike traditional hospital settings, ASCs offer a high-throughput environment tailored for elective surgeries like dacryocystorhinostomy, which helps decrease facility fees and patient waiting times. This transition is supported by superior workflow metrics; for instance, an article in ASC News from December 2024 regarding ophthalmology trends noted that the average operating room turnover time in ambulatory facilities was approximately 11.9 minutes, illustrating the agility that encourages payers and surgeons to move routine interventions to outpatient settings.

Concurrently, the implementation of antibiotic stewardship protocols is emerging as a crucial trend in response to the rising prevalence of drug-resistant pathogens in lacrimal infections. As resistance to standard prophylactic treatments grows, clinicians are shifting from empirical prescribing to culture-guided pharmacotherapy to avoid treatment failures in acute dacryocystitis. This change is vital given the increasingly complex bacteriological profile of the condition; according to a February 2024 study by the National Institutes of Health on adult dacryocystitis, methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa each constituted 28.1% of isolated pathogens in acute cases, accelerating the global adoption of targeted antimicrobial strategies.

Key Market Players

  • Viatris Inc.
  • GlaxoSmithKline PLC
  • FCI Ophthalmics Inc.
  • Merck & Co., Inc.
  • Kaneka Corporation
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Orex Pharma Pvt Ltd

Report Scope

In this report, the Global Dacryocystitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dacryocystitis Market, By Indication

  • Acute
  • Chronic
  • Congenital
  • Dacryocystitis
  • Other

Dacryocystitis Market, By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies

Dacryocystitis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dacryocystitis Market.

Available Customizations:

Global Dacryocystitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dacryocystitis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Acute, Chronic, Congenital, Dacryocystitis, Other)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Dacryocystitis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dacryocystitis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Dacryocystitis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Dacryocystitis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Distribution Channel

7. Europe Dacryocystitis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Dacryocystitis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Dacryocystitis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Dacryocystitis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Dacryocystitis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Dacryocystitis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Dacryocystitis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Dacryocystitis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Dacryocystitis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Dacryocystitis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Dacryocystitis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Dacryocystitis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Dacryocystitis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Dacryocystitis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Dacryocystitis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Dacryocystitis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Distribution Channel

10. South America Dacryocystitis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dacryocystitis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Dacryocystitis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Dacryocystitis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Dacryocystitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Viatris Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GlaxoSmithKline PLC
  • 15.3. FCI Ophthalmics Inc.
  • 15.4. Merck & Co., Inc.
  • 15.5. Kaneka Corporation
  • 15.6. Aurobindo Pharma Limited
  • 15.7. Bausch Health Companies Inc.
  • 15.8. Orex Pharma Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer